Volume : 09, Issue : 11, November – 2022
Title:
11.AN REVIEW ON ANTI DIABETIC BI-LAYERED MODIFIED RELEASE TABLETS
Authors :
Akshay Dipak Fulari, A.A.Harsulkar
Abstract :
The aim of the current study work was to formulate and assess a fixed dose mixture tablet of instant release oral solid dosage form comprising two anti-diabetic drugs (linagliptin and metformin hydrochloride) for managing of diabetes mellitus type 2.The innovator drug product (Jentadueto Tablet) was evaluated for the various evaluation parameters, which have been taken into consideration during the drug product development. Pre-formulation evaluation was accomplished to safeguard better parameters of formulated drug product. On the result of pre-formulation evaluation and innovator drug product characterization, the model drug product was recognized in various steps. The established formulation was augmented for different excipients. The instant release film covered tablet of linagliptin and metformin HCl was expressed and augmented at laboratory scale. The individual steps (procedures) were improved for the same and the scale-up contemplation have been engaged into account certify the product performance at pilot plant-up to commercial scale-up. Keywords: anti-diabetic, linagliptin, metformin.
Cite This Article:
Please cite this article in press Akshay Dipak Fulari et al, An Review On Anti Diabetic Bi-Layered Modified Release Tablets.,Indo Am. J. P. Sci, 2022; 09(11).
Number of Downloads : 10
References:
1. Sicree R., Shaw J., Zimmet P. Prevalence and projections. In: Gan D (ed.). Diabetes Atlas International Diabetes Federation, 3rdedn. International Diabetes Federation, Brussels, Belgium, 2006; 16- 104.
2. Clifford J. Bailey., Caroline D. Antidiabetic drugs, The British Journal of Cardiology, 2003; 10:128–36.
3. Halimi S., Schweizer A., Minic B., Foley J., Dejager S. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet, Vascular Health and Risk Management, 2008; 4(3):481–492.
4. Gohel N., Patel D.M., Patel K., Modi J. Formulation Development and Evaluation of Modified Release Tablet using a Fixed Dose Combination of Antidiabetic Agents, International Journal of Pharmaceutical Sciences Review and Research, 2017; 42(2):139- 145.
5. Blonde L., Juan Z.T.S. Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus, Advances in Therapy, 2012; 29(1):1- 13. DOI 10.1007/s12325-011-0094-1.
6. Khan M.D.P., Basha S.A.A., Mudabbir M.A.H. Formulation and Evaluation of Bilayer Matrix Tablets for Controlled Delivery of Metformin HCl and Vildagliptin, 2014; 6(2):6739-6756.
7. Kupsal K., Mudigonda S., Nyayapathi V.B.K.S., Neelala K., Hanumanth S.R. Metformin Combinatorial Therapy for Type 2 Diabetes Mellitus, Journal of Metabolic Syndrome, 2016; 5:210. doi: 10.4172 / 2167-0943.1000210.
8. Prajapati T.K. Development and Evaluation of Combination Formulation for the Immediate Delivery of Vildagliptin HCl and the Sustained Delivery of Metformin, International Journal of Current Advanced Research, 2018; 74:12097-12104.
9. Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. Int J Clin Pract. 2013;67(12):1283–1293.
10. Boehringer Ingelheim. JENTADUETO (linagliptin and metformin) tablets. Prescribing information. 2014. Available from: http://hcp.tradjenta.com/. Accessed July 16, 2014.
11. Boehringer Ingelheim. JENTADUETO (linagliptin and metformin) tablets. Summary of product characteristics. 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002279/ human_med_001574.jsp&mid=WC0b01ac058001d124. Accessed July 31, 2014.
12. IDF Clinical Guidelines Task Force. Global guidelines for type 2 diabetes. Brussels: international diabetes federation. 2012. Available from: http://www. idf.org/global-guideline-type-2-diabetes-2012. Accessed July 31, 2014.
13. NICE. Type 2 Diabetes: the management of type 2 diabetes: NICE clinical guideline 87. National Institute for Health and Clinical Excellence. 2009. Available from: http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf. Accesse July 31, 2014.
14. Forst T, Pfützner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother. 2012;13(1):101–110.
15. Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice. J Endocrinol. 2012;214(3):381–387.
16. van Genugten RE, van Raalte DH, Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab. 2012;14(2):101–111.
17. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab. 2004;17(6):336–342.
18. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagonlike peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24(3):489–494.
19. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29(4 pt 2):S28-S35.
20. Thondam SK, Cross A, Cuthbertson DJ, Wilding JP, Daousi C. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagonlike peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med. 2012;29(8):e205-e210.